Eltrombopag is a drug that is used to treat thrombocytopenia (abnormally low platelet counts) and severe aplastic anemia. It is offered under the trade names Promacta and others. Outside of the United States, Promacta (eltrombopag) is marketed as Revolade® by Novartis. It’s an agonist for the thrombopoietin receptor. Eltrombopag was discovered through cooperation between GlaxoSmithKline and Ligand Pharmaceuticals and is now owned by Novartis Pharmaceuticals. Idiopathic thrombocytopenic purpura (ITP) and cirrhosis related to hepatitis C have both been proven to be beneficial with eltrombopag (in which low platelet counts may be a contraindication for interferon treatment). Eltrombopag 50 mg/day was linked with a significantly higher response rate than placebo in adult patients with chronic idiopathic thrombocytopenic purpura after six weeks of therapy in a phase III trial (ITP). When taken together, some drugs can make eltrombopag less effective. It should be taken 2 hours before or 4 hours after other medicines such as an antacid, aluminum, calcium, iron, magnesium, selenium, or zinc.
In persons with chronic immune thrombocytopenic purpura (ITP), a bleeding disorder characterized by a shortage of platelets in the blood, Romiplostim is used to avoid bleeding episodes. Romiplostim is prescribed for adults and children over the age of one. Romiplostim is not a cure for ITP, and it will not restore normal platelet levels if you have it. When all previous therapies have failed, Romiplostim is used. Romiplostim is a fusion protein analog of thrombopoietin, a hormone that regulates platelet formation. It is commercialized under the brand names Nplate and others. Its action is to encourage the patient’s megakaryocytes to generate platelets at a faster rate than normal, outpacing the immune system’s ability to destroy them. Death, myalgia, joint and extremities discomfort, sleeplessness, thrombocytosis, which can lead to potentially lethal clots, and bone marrow fibrosis, which can lead to a hazardous drop in red blood count, are all possible side effects of this procedure.
Avatrombopag (Doptelet) is a drug used to treat thrombocytopenia (low platelets) in individuals who are about to have a medical or dental operation. In 2018 it was licensed for medical usage in the United States, and in 2019 it was approved in the European Union. Other medications, including prescription and over-the-counter medications, vitamins, and herbal items, may interact with avatrombopag.
Oprelvekin is recombinant interleukin eleven (IL-11), a thrombopoietic growth factor that promotes hematopoietic stem cell and megakaryocyte progenitor cell proliferation and induces megakaryocyte maturation, resulting in increased platelet production. Neumega is the brand name for this product. In adult patients with non-myeloid malignancies who are at high risk of severe thrombocytopenia, Neumega is used to avoid severe thrombocytopenia and reduce the need for platelet transfusions after myelosuppressive treatment. Patients who had undergone significant thrombocytopenia after the previous chemotherapy round were shown to be effective. There were no probable interactions when GM-CSFs like filgrastim or Sargramostim were used simultaneously. In addition, no additional interactions have been discovered. Interactions with medications that are metabolized by the P450 enzyme are unlikely. This drug is administered subcutaneously.
Lusutrombopag is a protein that boosts the synthesis of platelets (blood-clotting cells) in your body. Lusutrombopag increases platelets in the blood, which reduces the risk of bleeding. Lusutrombopag is a medication that is used to treat thrombocytopenia (a shortage of platelets in the blood) in adults with chronic liver disease who are going to have a medical procedure. Shionogi is a company that makes and sells it in Japan. The US Food and Drug Administration (FDA) approved it in July 2018, and NICE approved it in January 2020. In February 2019, the European Union approved it for medical use.
Sources and references : https://www.drugs.com/drug-class/platelet-stimulating-agents.php